黑色素瘤
医学
达布拉芬尼
腺苷
腺苷酸
癌症研究
癌症
曲美替尼
靶向治疗
转移
下调和上调
MAPK/ERK通路
威罗菲尼
内科学
激酶
腺苷受体
转移性黑色素瘤
生物
受体
生物化学
基因
细胞生物学
兴奋剂
作者
Arabella Young,Shin Foong Ngiow,Jason Madore,Julia Reinhardt,Jennifer Landsberg,Arash Chitsazan,Jai Rautela,Tobias Bald,Deborah Sim Barkauskas,Elizabeth Stephanie Ahern,Nicholas D. Huntington,Dirk Schadendorf,Georgina Venetia Long,Glen M. Boyle,Michael Hölzel,Richard A. Scolyer,Mark John Smyth
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2017-06-26
卷期号:77 (17): 4684-4696
被引量:101
标识
DOI:10.1158/0008-5472.can-17-0393
摘要
Abstract Increasing evidence exists for the role of immunosuppressive adenosine in promoting tumor growth and spread in a number of cancer types, resulting in poor clinical outcomes. In this study, we assessed whether the CD73-adenosinergic pathway is active in melanoma patients and whether adenosine restricts the efficacy of clinically approved targeted therapies for commonly mutated BRAFV600E melanoma. In AJCC stage III melanoma patients, CD73 expression (the enzyme that generates adenosine) correlated significantly with patients presenting nodal metastatic melanoma, suggesting that targeting this pathway may be effective in advanced stage disease. In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells. Inhibition of BRAF and MEK in combination with the A2A adenosine receptor provided significant protection against tumor initiation and metastasis formation in mice. Our results suggest that targeting adenosine may enhance therapeutic responses for melanoma patients receiving targeted or immune-based therapies. Cancer Res; 77(17); 4684–96. ©2017 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI